Company Overview of Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics in oncology. The company’s lead product candidate is entinostat, an epigenetic therapy for treatment-resistant cancers, such as breast cancer and lung cancer, as well as other indications comprising solid tumors and hematological malignancies. Its Entinostat is an oral histone deacetylase inhibitor that targets cancer cell growth and resistance pathways that limit the effectiveness and durability of cancer therapies. The company has a collaborative research and development agreement with the National Cancer Institute; and Genentech. Syndax Pharmaceuticals, In...
400 Totten Pond Road
Waltham, MA 02451
Founded in 2005
Key Executives for Syndax Pharmaceuticals, Inc.
Chief Executive Officer and Director
President and Chief Operating Officer
Co-Founder and Chief Technology Officer
Compensation as of Fiscal Year 2015.
Syndax Pharmaceuticals, Inc. Key Developments
Syndax Pharmaceuticals, Inc. Enters Clinical Trial Collaboration with Genentech in Cancer Immunotherapy Combining Entinostat and Atezolizumab
Aug 26 15
Syndax Pharmaceuticals, Inc. announced that it has entered into a clinical collaboration with Genentech to evaluate the safety, tolerability and preliminary efficacy of Syndax's entinostat, an oral small molecule that targets immune regulatory cells (myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs)), in combination with Genentech's atezolizumab (MPDL3280A), a fully humanized monoclonal antibody targeting protein programmed cell death ligand 1 (PD-L1), in patients with triple-negative breast cancer. Triple-negative breast cancer is estimated to account for 10-20% of all diagnosed breast cancers and is characterized by a lack of expression of estrogen receptor (ER-), progesterone receptor (PR-) and HER2 (HER2-) on the breast cancer cells. Syndax will be responsible for conducting the Phase 1b/2 clinical trial in triple-negative breast cancer and the agreement includes a provision where the parties may extend the collaboration to include a Phase 3 clinical trial as well as additional trials in new indications of mutual interest.
Syndax Pharmaceuticals Announces Management Changes
Jun 23 15
Syndax Pharmaceuticals has named Briggs Morrison as CEO and a member of the board, and Michael Metzger as president and COO. Morrison joins Syndax from AstraZeneca, where he was chief medical officer. He replaces Arlene Morris in the CEO role, who left in May to pursue other endeavors, said a company spokeswoman. Metzger joins from Regado Biosciences, where he was president and CEO through the company's strategic merger with Tobira Therapeutics.
Briggs Morrison to Join Syndax Pharmaceuticals as Head of Global Late-Stage Drug Development
Jun 15 15
Outgoing Chief Medical Officer of AstraZeneca Briggs Morrison will join Syndax Pharmaceuticals. Morrison, who joined the pharmaceutical company in 2012, is also serving the company as head of global late-stage drug development.
Similar Private Companies By Industry
Recent Private Companies Transactions
June 1, 2015
January 7, 2015
September 18, 2014
Most Searched Private Companies
Sponsored Financial Commentaries